A B S T R A C T An increase
INTRODUCTION
Whereas folate deficiency is a well-recognized feature of chronic anticonvulsant therapy (1) (2) (3) , the mechanism by which this happens is still controversial. Malabsorption of folate has been reported to occur (4-6) but has not been confirmed (7) (8) (9) (10) (11) .
The fact that anticonvulsant drugs are known to induce hepatic enzymes (12, 13) has led to a further series of hypotheses. First, Richens and Waters (14) have suggested that folate deficiency may arise by induction of the enzymes involved in folate metabolism.
Second, Maxwell et al. (15) proposed that it might be a result of an increase in the demand for the folate This work was presented in part at the XVII Congress of the Intemational Society of Haematology, Paris, France, [23] [24] [25] [26] [27] [28] [29] July 1978. coenzymes required, either for anticonvulsant drug hydroxylation or for other hepatic enzymes induced by these drugs.
Increased catabolism of folate has also been suggested as the cause of the folate deficiency observed in many other clinical conditions, such as pregnancy, malignancy, hemolytic anaemia, and inflammatory disease (16) .
Until recently the mechanism of folate catabolism was not known, and it was therefore not possible to confirm or refute the above-mentioned hypothesis. A number of studies in rats have shown that a tracer dose of high specific activity [3H]pteroylglutamate (PteGlu)1 becomes fully equilibrated into the tissue folate polyglutamate pools after periods of 2 or 3 d (17) . With such a tracer dose to label the endogenous pools we have recently elucidated the mechanism of folate catabolism in the rat (18) , and have shown that it proceeds via cleavage of the C9-N10 bond of the molecule to yield pteridines, which are retained by the liver and released slowly (19) , and p-aminobenzoylglutamate (pABGlu), most of which is first acetylated to produce acetamidobenzoylglutamate (ApABGlu) and then rapidly excreted in the urine (18) . In the 1st 3 d after administration of labeled PteGlu, i.e., during the equilibration of the tracer dose, a complex mixture of folate derivatives is found in the urine (18, (20) (21) (22) (23) (24) (25) . After this time, however, only cleaved folate catabolites are found in the urine (20 (27) . (c) Group C consisted of two cages of five mice in each group. Diphenylhydantoin-treated mice receivedl 1.0 mg/mouse (-50 (29) . The pAB was then extracted with diethylether in which it was highly soluble at pH 3.75. Each sample was extracted three times with 5 ml of diethylether, the ether evaporated to dryness, and then the sample was reconstituted with 1 ml of distilled water and 10 ml toluene Triton X-100 (Rohm and Haas Co., Philadelphia, Pa. in toluene:Triton X-100 scintillation fluid (31) with a Packard liquid scintillation counter (Packard Instrument Co., Downers Grove, Ill.). Column chromatography. Analysis of the folate catabolites in mouse urine was performed on QAE.A25 anion exchange resin (Pharmacia Inc., Uppsala, Sweden) as previously described (18, 20 The variation in excretion between the different groups is because the proportion of the tritium label on the pAB part of the molecule which differs between the batches of [3H]PteGlu used. However, the same batch was used for both control and treated groups in each study.
Comparison of [3H]pAB-excreted radioactivity on a daily basis in control, diphenylhydantoin-, and phenobarbitone-treated mice. Estimation of these catabolites in the 1st 3 d was similar in all treated groups when compared with controls and phenobarbitone-treated groups (Fig. 2) . After the 4th d however, radioactive excretion settled to an almost constant level. There was a definite increase in excretion of these catabolites in all treated groups when compared with controls or phenobarbitonetreated animals (Fig. 2) . Mean Comparison of cumulative excretion of both total and [3H]pAB radioactivity in controls, diphenylhydantoin-, and phenobarbitone-treated mice. Cumulative excretion of both total and [3H]pAB radioactivity was calculated for the 1st 3 d and then for the subsequent days of the experiment for each group.
There was no statistical difference between the cumulative excretion in either total or [3H]pAB radioactivity in the 1st 3 d in any of the treated groups when compared with control or phenobarbitonetreated animals (Table II) . However, there was a statistically significant increase in the cumulative excretion of both total and [3H]pAB radioactivity noted from during day 4-14 in group A and 4-10 in groups B and C (Table II) in all diphenylhydantoin-treated groups when compared with controls and phenobarbitonetreated animals (Table II) .
To relate these results to the total dose of [3H]PteGlu administered, the mean percentage of excreted dose was calculated and is given in Table II .
Chromatographic analysis of mouse urines. The results clearly indicate that diphenylhydantoin causes an increase in total radioactive excretion after day 3 ( Table I ) and also that this is a result of [3H]pABcontaining metabolites (Fig. 2) . To preclude the possibility that these increases were not in fact a result of increased catabolism but to diphenylhydantoin-mediated release of intact folates, a series of chromatographic studies were undertaken. Urines from both control and diphenylhydantoin-treated animals were analyzed by column chromatography as previously described (18, 20 (17, 18) . During the course of catabolism the folate molecules are cleaved into pteridines and pABGlu. The synthesis of high specific activity [3H]PteGlu is such that it distributes the radioactivity within the original molecule in such a way that both sets ofcatabolites are labeled after cleavage (18, 30) (Fig. 1) . In addition, it has now become apparent that initial estimates showing that only a small proportion of3H was attached to the pteridine were inaccurate (30) and that as much as 25% of the label resides at C7. Previous studies in this laboratory have qualitatively analyzed the daily excreted folates after injection of [3H]PteGlu in rats (20) . The pteridine catabolites are retained by the liver and excreted slowly whereas most of the pABGlu is These data are compatible with earlier studies which suggested that there is more than one pool of body folate (33) (34) (35) : a "newly absorbed" pool which has a short biological half-life and a tissue pool which has a longer half-life.
The effect of diphenylhydantoin was investigated at three different doses: a very low dose, which was considerably less than the therapeutic dose (1/40); a therapeutic dose; and a higher than therapeutic dose (27) . It is probably not possible to compare these dosages with human dose regimes by merely correcting for weight and volume because the species difference may be important. Nevertheless, the effect ofdiphenylhydantoin was observed at all three doses, even the exceptionally low dose. There was no effect on the rapid urinary excretion of radioactivity in the 1st 3 d. From the 4th d onward, there was a definite increase in both daily (Table I ) and cumulative excretion of total radioactivity (Table II) and of [3H]pAB ( Fig. 2 ; Table II), which was most obvious at the highest dosage of diphenylhydantoin.
It is interesting to note that this increased excretion of folate catabolites was only observed at a time when cleaved products were maximal in the urine. This would suggest that diphenylhydantoin increased the quantity of catabolites excreted from the second folate metabolic pool. It is unlikely that this alteration in excretion could be caused by changes in diet alone because both control and treated animals were maintained on identical diets under similar conditions. It is also improbable that it is simply a result of increased excretion of intact folate, because, in this case one would expect an effect in the 1st 3 d as well. Furthermore, the qualitative analysis of the urine showed that there was no difference in the pattern of catabolites excreted in treated and control mice, both urines containing cleaved products from the 3rd d onwards. A further alternative is that diphenylhydantoin might induce rapid cellular or renal clearance of the metabolites. However, it has been our experience in other studies involving the measurement of acetylation of pABGlu that this compound and its acetylated counterpart are excreted within a matter of hours. This is in accordance with a large body of literature showing similar clearance rates for similar compounds (36 (33) (34) (35) , that such increased turnover might lead to the increased incidence of folate deficiency observed in patients on long-term diphenylhydantoin treatment (1-3).
Administration of phenobarbitone had no significant effect on the rate of folate catabolism when compared with controls. This observation concurs with the clinical impression that folate deficiency is more common during therapy with diphenylhydantoin than with phenobarbitone (1, 37) .
The mechanism for diphenylhydantoin-induced catabolism, however, is not clear. Because both the anticonvulsant drugs investigated induce hepatic enzymes equivalently (12, 13) this appears unlikely to be the mechanism as previously suggested (14, 15) . It is, of course, possible that diphenylhydantoin induces a specific enzyme, either folate dependent or nonspecifically related, that phenobarbitone does not. Alternatively, it is possible that they have entirely different mechanisms of action as demonstrated in their effects on calcium and vitamin D metabolism (38) . Perhaps a more attractive explanation lies in the known chemical instability of the folate coenzymes. It is easy to imagine a wide range of possibilities from alteration of the environment within cells to accumulation of more labile forms, which could readily lead to marked increases and their destruction.
These results conflict with those of Krumdieck et al. (35) . While working with a single patient they found diphenylhydantoin increased excretion of newly absorbed PteGlu but did not increase catabolism. How- ever, these workers used [2-14C] PteGlu which upon catabolism produces a labeled pteridine only, which has been found to be further metabolized to produce several different pteridines which are retained by the liver for prolonged periods (19) . This retention may obscure the clear increase in the catabolic rate effected by diphenylhydantoin (Fig. 2) which was observed when the rapidly excreted catabolites ApABGlu and pABGlu were measured.
